Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival (PFS) for its subcutaneous bispecific ...

Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie ...

Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other care providers help.

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi as a first-line treatment for diffuse large B-cell lymphoma (DLBCL). | A ...

Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...